BR112012005837A8 - Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática - Google Patents

Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática

Info

Publication number
BR112012005837A8
BR112012005837A8 BR112012005837A BR112012005837A BR112012005837A8 BR 112012005837 A8 BR112012005837 A8 BR 112012005837A8 BR 112012005837 A BR112012005837 A BR 112012005837A BR 112012005837 A BR112012005837 A BR 112012005837A BR 112012005837 A8 BR112012005837 A8 BR 112012005837A8
Authority
BR
Brazil
Prior art keywords
treatment
pain
pancreatitis
pancreatic
pancreatic insufficiency
Prior art date
Application number
BR112012005837A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012005837A2 (pt
Inventor
M Venkatesh Gopi
Perrett Stephen
Thieroff-Ekerdt Ruth
Efthymiopoulos Konstantino
Original Assignee
Aptalis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43730817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012005837(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharma Ltd filed Critical Aptalis Pharma Ltd
Publication of BR112012005837A2 publication Critical patent/BR112012005837A2/pt
Publication of BR112012005837A8 publication Critical patent/BR112012005837A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112012005837A 2009-09-17 2010-09-17 Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática BR112012005837A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24346709P 2009-09-17 2009-09-17
PCT/US2010/049203 WO2011035079A1 (en) 2009-09-17 2010-09-17 Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency

Publications (2)

Publication Number Publication Date
BR112012005837A2 BR112012005837A2 (pt) 2017-05-30
BR112012005837A8 true BR112012005837A8 (pt) 2017-10-10

Family

ID=43730817

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005837A BR112012005837A8 (pt) 2009-09-17 2010-09-17 Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática

Country Status (23)

Country Link
US (2) US8784884B2 (https=)
EP (1) EP2477645B1 (https=)
JP (1) JP5877399B2 (https=)
KR (1) KR101771752B1 (https=)
CN (2) CN102630164B (https=)
AR (1) AR078291A1 (https=)
AU (1) AU2010295494B2 (https=)
BR (1) BR112012005837A8 (https=)
CA (1) CA2774269C (https=)
CL (1) CL2012000658A1 (https=)
CO (1) CO6531419A2 (https=)
ES (1) ES2690661T3 (https=)
HK (1) HK1218886A1 (https=)
IL (2) IL218656A (https=)
MX (1) MX2012003214A (https=)
MY (1) MY161843A (https=)
NZ (1) NZ599143A (https=)
RU (1) RU2570376C2 (https=)
SA (1) SA110310695B1 (https=)
TW (2) TW201639545A (https=)
UY (1) UY32896A (https=)
WO (1) WO2011035079A1 (https=)
ZA (1) ZA201202761B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
JP5966202B2 (ja) 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
ES2657673T3 (es) * 2010-10-01 2018-03-06 Aptalis Pharma Limited Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad
CA2843556A1 (en) * 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
CA2920844A1 (en) 2013-08-09 2015-02-12 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US20230138700A1 (en) * 2020-03-30 2023-05-04 Jai WALL Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JP2000505801A (ja) 1996-02-09 2000-05-16 クアドラント・ホールディングズ・ケンブリッジ・リミテッド トレハロースを含む固形製剤
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
CN1156308C (zh) * 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004071374A2 (en) 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
WO2005042012A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
EP1755656B1 (en) * 2004-05-24 2010-07-07 Novozymes A/S Enzymes for pharmaceutical use
WO2006044529A1 (en) * 2004-10-14 2006-04-27 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN101208429A (zh) * 2005-06-24 2008-06-25 诺维信公司 用于药物用途的脂肪酶
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
KR101555058B1 (ko) 2005-07-29 2015-09-22 애보트 래버러토리즈 게엠베하 살균된 판크레아틴 분말의 제조방법
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
AU2007267560B2 (en) * 2006-05-26 2010-10-21 Nestec S.A. Methods of use and nutritional compositions of Touchi Extract
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
JP5966202B2 (ja) 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
EP2328566A1 (en) 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency

Also Published As

Publication number Publication date
MX2012003214A (es) 2012-08-01
BR112012005837A2 (pt) 2017-05-30
TW201639545A (zh) 2016-11-16
HK1218886A1 (zh) 2017-03-17
CN102630164A (zh) 2012-08-08
JP5877399B2 (ja) 2016-03-08
ZA201202761B (en) 2012-12-27
KR20120100915A (ko) 2012-09-12
UY32896A (es) 2011-02-28
TWI572372B (zh) 2017-03-01
CO6531419A2 (es) 2012-09-28
SA110310695B1 (ar) 2014-11-26
RU2570376C2 (ru) 2015-12-10
TW201113052A (en) 2011-04-16
JP2013505255A (ja) 2013-02-14
EP2477645A4 (en) 2014-06-25
KR101771752B1 (ko) 2017-08-25
RU2012113253A (ru) 2013-10-27
CA2774269A1 (en) 2011-03-24
EP2477645A1 (en) 2012-07-25
IL218656A0 (en) 2012-05-31
CL2012000658A1 (es) 2012-09-28
CN102630164B (zh) 2015-09-16
IL218656A (en) 2017-12-31
ES2690661T3 (es) 2018-11-21
US8784884B2 (en) 2014-07-22
CA2774269C (en) 2017-03-21
US20140287035A1 (en) 2014-09-25
WO2011035079A1 (en) 2011-03-24
CN105214073A (zh) 2016-01-06
AR078291A1 (es) 2011-10-26
NZ599143A (en) 2014-05-30
EP2477645B1 (en) 2018-08-15
AU2010295494B2 (en) 2014-09-25
US20110064799A1 (en) 2011-03-17
US20160051472A9 (en) 2016-02-25
IL245875A0 (en) 2016-07-31
AU2010295494A1 (en) 2012-03-29
MY161843A (en) 2017-05-15

Similar Documents

Publication Publication Date Title
BR112012005837A8 (pt) Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática
MX342128B (es) Compuestos farmaceuticos.
WO2010059004A3 (ko) 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MY152033A (en) Anti-siglec-15 antibody
IN2012DN00624A (https=)
BR112012004377A2 (pt) terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
EA017150B9 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
BR112013007640A2 (pt) "composição, forma de dosagem, pacote, processo para a preparação da composição, processo para a preparação da forma de dosagem, método para tratamento ou prevenção de um distúrbio ou afecção associada a uma defeciência de enzima digestiva, método de terapia de substituição de enzima pacnreática e método para aperfeiçoar resultados nutricionais e de crescimento"
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
EP2440210A4 (en) METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
BR112012009123A2 (pt) novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
BRPI0922301A2 (pt) combinações de inibidor de hsp90
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2010007242A (es) Composiciones farmaceuticas que comprenden granulos de lipasa microbiana purificada y metodos para prevenir o tratar trastornos digestivos.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2011082245A3 (en) Metalloenzyme inhibitor compounds
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: APTALIS PHARMA LIMITED. (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL